Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Raw Materials (2020 - 2025)

Puma Biotechnology's Raw Materials history spans 6 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Raw Materials fell 55.28% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 55.28%, while the annual FY2025 figure was $3.2 million, 55.28% down from the prior year.
  • Raw Materials reached $3.2 million in Q4 2025 per PBYI's latest filing, down from $3.6 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $7.2 million in Q4 2024 to a low of $211000.0 in Q3 2024.
  • Average Raw Materials over 5 years is $3.6 million, with a median of $3.6 million recorded in 2025.
  • Peak YoY movement for Raw Materials: crashed 83.74% in 2024, then skyrocketed 1626.07% in 2025.
  • A 5-year view of Raw Materials shows it stood at $4.6 million in 2021, then crashed by 63.25% to $1.7 million in 2022, then surged by 239.07% to $5.7 million in 2023, then rose by 26.17% to $7.2 million in 2024, then crashed by 55.28% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Raw Materials are $3.2 million (Q4 2025), $3.6 million (Q3 2025), and $6.5 million (Q2 2025).